Jagsonpal Pharmaceuticals delivered robust financial performance in the quarter ended June 2026, with standalone net profit rising 22.15% year-on-year to ₹13.18 crore compared to ₹10.79 crore in the corresponding quarter of the previous year. The company's stock surged 10% to ₹254.67 following the strong quarterly results announcement. The company also demonstrated strong sequential growth, with profit increasing 50.68% quarter-on-quarter from ₹8.76 crore in Q4 FY26. According to the latest financial results approved by the Board of Directors on July 29, 2026, this significant profit growth demonstrates the company's operational efficiency and market positioning during the quarter. The company significantly outperformed the industry average of 11.6% growth recorded by Pharmarack for the Indian pharmaceutical market.
The pharmaceutical company's sales increased 8.76% to ₹82.23 crore in Q1 FY2026, up from ₹75.60 crore in the same period last year. As reported in the latest financial results, this revenue growth indicates steady business expansion and market demand for the company's products during the quarter. The company's revenue from operations increased by ₹66 million compared to the same period last year, with gross profit rising to ₹536 million from ₹487 million, and gross margin expanding to 65.2% from 64.4%. The company's profit before tax (PBT) climbed 22.52% YoY to ₹17.68 crore in the quarter ended June 2026, compared to ₹144 million in the same period last year, with PAT margin improving to 16.0% from 14.3% in the previous year.
The company's operating EBITDA margin expanded significantly to 23.2% in the June 2026 quarter, compared to 20.8% in the corresponding quarter of the previous year. According to the latest financial data, operating EBITDA grew 21.4% to ₹19.1 crore, with the margin expansion of 241 basis points reflecting better cost management and operational efficiency. This margin expansion was driven by improved medical representative productivity and higher sales across key brands, with total expenses growing only 5.4% year-on-year despite revenue growth of 8.76%, demonstrating significant operating leverage. Managing Director and CEO Manish Gupta highlighted that Q1 FY27 reflects sustained traction in the business, with revenue growing 9% YoY driven by higher MR productivity and continued strength across key brands. The company also completed the integration of Aequitas Healthcare, which has a revenue base of ₹53.3 crore, with management expecting the acquisition to contribute to higher revenue and profitability from the second half of FY27 and targeting EBITDA of more than ₹10 crore by the second year after integration.
During the quarter, Jagsonpal Pharmaceuticals completed the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited for ₹20.80 crore, with the transaction completed on July 17, 2026, after initially acquiring a 69.77% stake on July 7, 2026. This strategic acquisition marks the company's entry into the hospital supplies segment, providing immediate access to over 1,000 hospitals and relationships with more than 4,000 doctors. The company also completed its ₹40 crore equity share buyback at ₹250 per share in May 2026, which reduced the outstanding equity base and should boost Earnings Per Share (EPS) and improve return ratios in the medium term. Despite these significant capital deployments, the company maintained a robust cash reserves of ₹170 crore, highlighting the strength of its asset-light business model and free cash flow generation capabilities. The company's portfolio focuses on gynaecology, orthopaedics, dermatology and child-care segments.
The company's sequential recovery from Q4 FY26 indicates strong market demand and better field force productivity, with the 22.15% YoY jump in Q1 FY27 showing solid earnings momentum. Jagsonpal Pharmaceuticals significantly outperformed the industry with Pharmarack reporting 18.9% growth for Jagsonpal versus 11.6% for the IPM, leading to a 4 ranks improvement to #88 in the Indian pharmaceutical market. The company's disciplined capital allocation initiatives include the recent share buyback resulting in an ROCE improvement by 340 basis points, while maintaining a healthy cash balance. With a stronger business franchise, disciplined capital allocation, and multiple growth levers in place, the company remains confident of sustaining profitable growth while pursuing value-accretive inorganic opportunities. The company's clean debt-free balance sheet, active capital return via buybacks, and targeted inorganic expansion position it well to deliver sustainable long-term value in the pharmaceutical sector.
